The Week Ahead: Fed...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$1.87 0.07 | 3.89%
06/04/12 - 09:59 AM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 31.47M | 18.60M | 29.39M | 27.67M |
| Receivables | 6.09M | 5.32M | 2.72M | 4.69M |
| Inventories | 7.02M | 1.70M | 578.00K | 0.00 |
| Other Current Assets | 4.97M | 2.90M | 2.82M | 814.00K |
| Total Current Assets | 76.85M | 88.56M | 58.51M | 65.62M |
| Property, Plant & Equipment, Gross | 25.45M | 21.24M | 21.13M | 25.13M |
| Accumulated Depreciation & Depletion | 20.57M | 19.06M | 17.63M | 18.99M |
| Property, Plant & Equipment, Net | 4.88M | 2.18M | 3.51M | 6.14M |
| Intangibles | 0.00 | 0.00 | 0.00 | 428.00K |
| Other Non-Current Assets | 1.64M | 1.69M | 2.78M | 2.89M |
| Total Non-Current Assets | 6.52M | 3.87M | 6.29M | 9.45M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 83.38M | 92.43M | 64.80M | 75.08M |
| Accounts Payable | 2.93M | 1.40M | 11.79M | 1.32M |
| Short Term Debt | 101.00K | 586.00K | 890.00K | 1.13M |
| Other Current Liabilities | 1.71M | 700.00K | 1.36M | 983.00K |
| Total Current Liabilities | 23.76M | 20.70M | 24.39M | 24.89M |
| Long Term Debt | 75.37M | 56.41M | 58.75M | 48.50M |
| Deferred Income Taxes | 2.37M | 30.00K | 0.00 | 0.00 |
| Other Non-Current Liabilities | 9.26M | 12.67M | 20.27M | 21.73M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 87.01M | 69.10M | 79.02M | 70.23M |
| Total Liabilities | 110.77M | 89.80M | 103.40M | 95.12M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -27.40M | 2.63M | -38.60M | -20.04M |
| Common Par | 988.00K | 985.00K | 781.00K | 630.00K |
| Additional Paid In Capital | 448.53M | 443.93M | 378.42M | 334.08M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -476.92M | -442.32M | -417.82M | -355.40M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 7.00K | 44.00K | 15.00K | 644.00K |
| Total Capitalization | 47.97M | 59.04M | 20.15M | 28.46M |
| Total Equity | -27.40M | 2.63M | -38.60M | -20.04M |
| Total Liabilities & Stock Equity | 83.38M | 92.43M | 64.80M | 75.08M |
| Total Common Shares Outstanding | 98.80M | 98.51M | 78.07M | 63.04M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 98.73M | 93.27M | 69.15M | 61.63M |
| Diluted Weighted Shares Outstanding | 98.73M | 93.27M | 69.15M | 61.63M |
| Number of Employees | 120 | 137 | 121 | 164 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DYAX
- Portfolio NameUser Type
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
- Userslarsen Portfolio 1
Latest DYAX Headlines from TheStreet
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
- Dyax, RF Micro: Early Volume Plays 12.02.09 | 08:12 am
- FDA Approves Two New Drugs: BioBuzz 12.02.09 | 07:12 am
Press Releases for DYAX
- Dyax Announces Extension Of Partnership With Bayer For Access To Dyax’s Fully-Human Antibody Phage Display Library - Business Wire 05.30.12 | 08:05 am
- Dyax Corp. To Participate In The Jefferies 2012 Global Healthcare Conference - Business Wire 05.29.12 | 07:05 am
- Dyax Launches HAE Diagnostic Testing Refund Program To Encourage Proper Diagnosis And Disease Management - Business Wire 05.24.12 | 10:05 am
- "Dyax Employees Gather At Their Burlington, MA Corporate Headquarters To Take Part In The "Cover The World With Smiles" Campaign. The Initiative Asks Those From Around The World To Take A Picture Of Their 'smile', The Primary Symbol Of Hereditary Angioedema Awareness Day, To Demonstrate That People Everywhere Are Banding Together To Raise Awareness Of The Condition." (Photo: Business Wire) - Business Wire 05.16.12 | 08:05 am
- Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, A Free IPhone Application For HAE Patients - Business Wire 05.11.12 | 07:05 am
- Dyax Corp. To Participate In The Deutsche Bank 37th Annual Healthcare Conference - Business Wire 05.01.12 | 07:05 am
- Dyax Corp. To Host First Quarter 2012 Earnings Call And Webcast - Business Wire 04.18.12 | 07:04 am
- Dyax And Eclipse Therapeutics Announce Oncology Antibody License Agreement - Business Wire 04.17.12 | 07:04 am
- Dyax Launches Hereditary Angioedema Genetic Counseling Program To Educate Patients And Family Members About Disease And Inheritance - Business Wire 04.11.12 | 07:04 am
- GE Healthcare And Dyax Announce Licensing Agreement For C-Met Imaging Peptides For Use In Colorectal, Lung And Liver Cancer Research - Business Wire 03.31.12 | 08:03 am
Partner Headlines for DYAX
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
